Cargando…

Pharmacogenomic testing and antidepressant response: problems and promises

Detalles Bibliográficos
Autores principales:	Smith, Tawny L., Nemeroff, Charles B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Psiquiatria 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115442/ https://www.ncbi.nlm.nih.gov/pubmed/32187320 http://dx.doi.org/10.1590/1516-4446-2019-0799

Ejemplares similares

Personalized medicine in psychiatry: problems and promises
por: Ozomaro, Uzoezi, et al.
Publicado: (2013)

Pharmacogenomics in depression and antidepressants
por: Bondy, Brigitta
Publicado: (2005)

Pharmacogenomics of antidepressant treatment effects
por: Licinio, Julio, et al.
Publicado: (2011)

Pharmacogenomic strategy for individualizing antidepressant therapy
por: Lin, Keh-Ming, et al.
Publicado: (2008)

Pharmacogenomics: A focus on antidepressants and atypical antipsychotics
por: Lister, Jonathan F.
Publicado: (2016)

Pharmacogenomics: the promise of personalized medicine.
por: Hood, Ernie
Publicado: (2003)

Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments
por: Lin, Eugene, et al.
Publicado: (2021)

Pharmacogenomics and Personalized Medicine
por: Cecchin, Erika, et al.
Publicado: (2020)

Pharmacogenomics in Palliative Medicine
por: Rao, Mahadev
Publicado: (2019)

Pharmacists as facilitators of pharmacogenomic guidance for antidepressant drug selection and dosing
por: Bishop, Jeffrey R.
Publicado: (2021)

Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy
por: Correia, Catarina, et al.
Publicado: (2022)

Can personalized medicine mitigate confirmation bias in mental health?
por: Perna, Giampaolo, et al.
Publicado: (2021)

Prenatal Pharmacogenomics: A promising area for research
por: Dorfman, Elizabeth H., et al.
Publicado: (2016)

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response
por: Biernacka, J M, et al.
Publicado: (2015)

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response
por: Biernacka, J M, et al.
Publicado: (2016)

Future directions in asthma pharmacogenomics
por: Weiss, Scott T.
Publicado: (2022)

Pharmacogenomics: From Basic Research to Clinical Implementation
por: Scheinfeldt, Laura B.
Publicado: (2021)

Response to: “Consistent terminology for medication-related problems in pharmacogenomic cases”
por: Korchia, Theo, et al.
Publicado: (2023)

Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation
por: Scott, Stuart A., et al.
Publicado: (2021)

Pharmacogenomics: an opportunity for personalised psychotropic prescribing in adults with intellectual disabilities
por: Perera, Bhathika, et al.
Publicado: (2022)

Pharmacogenomics in Personalized Medicine and Drug Metabolism
por: Chang, Wei-Chiao
Publicado: (2014)

Medication reconciliation to support pharmacogenomics implementation
por: Mosley, Scott A., et al.
Publicado: (2022)

Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics
por: Koromina, Maria, et al.
Publicado: (2020)

Pharmacogenomics: a key component of personalized therapy
por: Schwab, Matthias, et al.
Publicado: (2012)

The Potential Roles of Pharmacists in the Clinical Implementation of Pharmacogenomics
por: Maruf, Abdullah Al, et al.
Publicado: (2023)

Preface to Special Issue on ‘Cytochrome P450 Variation in Pharmacogenomics’
por: Rettie, Allan E., et al.
Publicado: (2018)

Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression
por: Williams, L M, et al.
Publicado: (2016)

General considerations for integrating pharmacogenomics into mainstream medical practice
por: Patrinos, George P
Publicado: (2010)

Advances in Personalized Medicines along with Functional Genomics and Pharmacogenomics
por: Lee, Su-Jun
Publicado: (2021)

Demand for Pharmacogenomics and Personalized Medicine in the United Arab Emirates
por: Jarrar, Yazun, et al.
Publicado: (2022)

The Future of Pharmacogenomics Requires New Discoveries and Innovative Education
por: Giardina, Emiliano, et al.
Publicado: (2022)

Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects
por: Panteleev, Mikhail A, et al.
Publicado: (2015)

Consistent terminology for medication-related problems in pharmacogenomic cases
por: Polasek, Thomas M., et al.
Publicado: (2023)

Editorial: The role of pharmacogenomics in addressing health disparities: the path, the promise, and the barriers
por: Roman, Youssef M.
Publicado: (2023)

Patient Perspectives of Barriers and Facilitators for the Uptake of Pharmacogenomic Testing in Veterans Affairs’ Pharmacogenomic Testing for the Veterans (PHASER) Program
por: Melendez, Karina, et al.
Publicado: (2023)

Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients
por: Dunlop, Boadie W.
Publicado: (2020)

Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?
por: van Westrhenen, Roos, et al.
Publicado: (2020)

Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication
por: Athreya, Arjun P., et al.
Publicado: (2019)

Public Attitudes toward Pharmacogenomic Testing and Establishing a Statewide Pharmacogenomics Database in the State of Minnesota
por: Zhang, Lusi, et al.
Publicado: (2022)

Is pharmacogenomics a reality? Challenges and oppurtunities for India
por: Banerjee, Moinak
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ickntvo5khkbt8lml7aqq9kc28